Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $5.6 million.

  • Exagen's Net Cash Flow rose 32991.0% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 31233.43%. This contributed to the annual value of -$14.5 million for FY2024, which is 4417.72% up from last year.
  • Per Exagen's latest filing, its Net Cash Flow stood at $5.6 million for Q3 2025, which was up 32991.0% from $18.8 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Net Cash Flow ranged from a high of $60.6 million in Q1 2021 and a low of -$20.7 million during Q2 2023
  • Moreover, its 5-year median value for Net Cash Flow was -$5.8 million (2021), whereas its average is -$1.1 million.
  • The largest annual percentage gain for Exagen's Net Cash Flow in the last 5 years was 186373.69% (2021), contrasted with its biggest fall of 15639.89% (2021).
  • Over the past 5 years, Exagen's Net Cash Flow (Quarter) stood at -$7.3 million in 2021, then increased by 13.8% to -$6.3 million in 2022, then soared by 227.44% to $8.0 million in 2023, then crashed by 99.99% to $1000.0 in 2024, then skyrocketed by 561800.0% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $18.8 million for Q2 2025, and -$10.8 million during Q1 2025.